NYSE:DHR
DANAHER CORP /DE/
A premier provider of life science tools and diagnostics driving precision medicine through continuous innovation and global market expansion.
Key Metrics
Investment Thesis
Bull Case
Danaher offers compelling value through its dominant market position in high-barrier-to-entry diagnostic segments where it commands premium pricing and consistent cash flow generation. The company's disciplined capital allocation strategy is evidenced by robust free cash flow supporting aggressive buybacks, which enhances shareholder returns while signaling confidence in long-term growth prospects. Continued innovation in precision medicine and the successful integration of its operating system across diverse business units position Danaher to capture value from the expanding global healthcare market.
Bear Case
Investors should be cautious regarding the year-over-year decline in net income from $7.21 billion in 2022 to $3.61 billion in 2025, which indicates potential structural headwinds or one-time costs affecting profitability. The substantial accumulated other comprehensive loss of -$207 million and significant long-term debt obligations of $18.42 billion increase financial leverage risks during periods of rising interest rates or economic downturns. Slower revenue growth compared to historical peaks may limit total shareholder return potential until the company can demonstrate a sustained recovery in top-line expansion.
About DANAHER CORP /DE/
Danaher Corporation is a global leader in life science tools and diagnostics, operating through segments that serve hospitals, clinical laboratories, and pharmaceutical industries with innovative technologies. The company specializes in high-precision instruments, automated laboratory systems, and advanced diagnostic solutions primarily in North America, Europe, and Asia. Its portfolio includes critical care monitoring, blood analysis, and genetic testing platforms that are essential for modern healthcare workflows.
Analysis
Management Discussion
Recent financial performance shows a resilient recovery with revenue growing to $24.57 billion in 2025, though net income has moderated to $3.61 billion reflecting ongoing margin pressures and strategic investments. Cash flow from operations of $6.42 billion demonstrates strong liquidity generation, enabling the company to fund capital expenditures of $1.16 billion while returning significant capital through $3.09 billion in share repurchases and $878 million in dividends. The decrease in revenue from 2022's peak of $31.47 billion suggests a stabilization after pandemic-related spikes, with management focusing on profitability over top-line growth to navigate current economic headwinds.
Industry Overview
The global life sciences industry is characterized by rapid technological advancement and increasing demand for precision diagnostics driven by aging populations and emerging infectious diseases. Companies in this sector face stringent regulatory environments requiring continuous investment in R&D to maintain competitive differentiation and secure market approval for new products. Consolidation trends are prevalent as larger entities acquire smaller innovators to expand their product portfolios and achieve economies of scale in manufacturing and distribution.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $31.47B | $23.89B | $23.88B | $24.57B |
| Cost of Revenue | $12.52B | $9.86B | $9.67B | $10.04B |
| Gross Profit | $18.95B | $14.03B | $14.21B | $14.52B |
| Operating Expenses | $10.26B | $8.83B | $9.34B | $9.83B |
| Operating Income | $8.69B | $5.20B | $4.86B | $4.69B |
| R&D | $1.75B | $1.50B | $1.58B | $1.60B |
| G&A | $8.52B | $7.33B | $7.76B | $8.23B |
| Stock-Based Comp | $336.0M | $306.0M | $288.0M | $298.0M |
| D&A | $2.22B | $2.17B | — | — |
| Depreciation | $738.0M | $675.0M | $721.0M | $750.0M |
| Amortization | $1.48B | $1.49B | $1.63B | $1.70B |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $-396.0M | $-158.0M | $-217.0M | $-457.0M |
| Interest Expense | $211.0M | $286.0M | — | — |
| Interest Income | $41.0M | $303.0M | $117.0M | $30.0M |
| Pre-Tax Income | $8.29B | $5.04B | $4.65B | $4.23B |
| Income Tax | $1.08B | $823.0M | $747.0M | $633.0M |
| Continuing Ops | $7.21B | $4.22B | $3.90B | $3.60B |
| Discontinued Ops | $0 | $543.0M | $0 | $14.0M |
| Net Income | $7.21B | $4.76B | $3.90B | $3.61B |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $7.21B | $4.76B | $3.90B | $3.61B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $15.88B | $13.94B | $9.50B | $12.76B |
| Accounts Receivable | $4.92B | $3.92B | $3.54B | $3.91B |
| Inventory | $3.11B | $2.59B | $2.33B | $2.49B |
| Prepaid Expenses | $1.86B | $1.56B | $1.55B | $1.74B |
| Other Current Assets | $6.00B | $5.86B | $2.08B | $4.62B |
| Long-Term Assets | $68.47B | $70.55B | $68.05B | $70.71B |
| PP&E (Net) | $3.96B | $4.55B | $4.99B | $5.53B |
| Intangibles | $20.30B | $20.75B | $18.57B | $17.82B |
| Goodwill | $39.75B | $41.61B | $40.50B | $43.15B |
| Operating Leases | $1.00B | $1.05B | $1.08B | $1.21B |
| Other LT Assets | $3.46B | $2.59B | $2.91B | $3.00B |
| Total Assets | $84.35B | $84.49B | $77.54B | $83.46B |
| Current Liabilities | $8.39B | $8.27B | $6.80B | $6.81B |
| Current Leases | $199.0M | $180.0M | $173.0M | $199.0M |
| Deferred Revenue | — | $1.47B | $1.30B | $1.35B |
| Taxes Payable | $691.0M | $582.0M | $568.0M | $532.0M |
| Other Current Liab | $2.00B | $1.23B | $218.0M | $-238.0M |
| Long-Term Liabilities | $25.87B | $22.72B | $21.19B | $24.12B |
| Long-Term Debt | $19.09B | $16.71B | $15.50B | $18.42B |
| LT Operating Leases | $863.0M | $954.0M | $968.0M | $1.08B |
| Other LT Liab | $1.71B | $1.39B | $1.36B | $1.38B |
| Total Liabilities | $34.26B | $31.00B | $27.99B | $30.92B |
| Shareholders' Equity | $50.09B | $53.49B | $49.55B | $52.54B |
| Retained Earnings | $39.20B | $41.07B | $44.19B | $46.89B |
| AOCI | $-2.87B | $-1.75B | $-3.22B | $-207.0M |
| Total L&E | $84.35B | $84.49B | $77.54B | $83.46B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $7.21B | $4.76B | $3.90B | $3.61B |
| Non-Cash Adjustments | $-371.0M | $2.24B | $3.52B | $1.98B |
| Working Capital Changes | $1.68B | $163.0M | $-736.0M | $819.0M |
| Cash from Operations | $8.52B | $7.16B | $6.69B | $6.42B |
| Capital Expenditures | $1.15B | $1.38B | $1.39B | $1.16B |
| Cash from Investing | $-2.23B | $-7.08B | $-1.98B | $-1.20B |
| Share Buybacks | — | — | $5.98B | $3.09B |
| Dividends Paid | $818.0M | $821.0M | $768.0M | $878.0M |
| Cash from Financing | $-2.57B | $-273.0M | $-8.38B | $-2.96B |
| FX Effect | $-306.0M | $59.0M | $-108.0M | $278.0M |
| Net Change in Cash | $3.41B | $-131.0M | $-3.79B | $2.54B |
| Beginning Cash | $2.59B | $6.00B | $5.86B | $2.08B |
| Ending Cash | $6.00B | $5.86B | $2.08B | $4.62B |
Frequently Asked Questions
How does DANAHER CORP /DE/ make money?
The company operates primarily through its Life Science Tools segment, which offers specialized instruments and consumables for clinical and research laboratories, alongside its Diagnostics segment providing in vitro diagnostic systems and assays. Revenue streams are further diversified by its presence in the Industrial segment, serving manufacturing and life science industries with automation solutions and process control technologies. These segments collectively generate over $24 billion in annual revenue supported by a robust portfolio of proprietary intellectual property.
What are the main risks for DHR?
Significant exposure to foreign exchange fluctuations can impact reported earnings given the company's substantial international operations and revenue generated outside the United States. Intense competition from both established industry giants and innovative startups may pressure pricing power and margin expansion in key diagnostic and instrumentation categories. Regulatory changes in healthcare reimbursement policies or stricter approval requirements for new medical devices could delay product launches or increase compliance costs. High levels of accumulated goodwill and intangible assets pose impairment risks if core business units underperform expectations.
What is DHR's competitive advantage?
Danaher leverages its unique Danaher Operating System (DOS) to drive operational excellence, continuous improvement, and rapid commercialization of new products across its global footprint. The company's extensive portfolio of patented technologies and strong brand recognition in the life sciences sector creates significant switching costs for customers dependent on high-reliability diagnostic equipment. Its decentralized management structure combined with centralized R&D capabilities allows for agile responses to emerging market needs while maintaining rigorous quality standards.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.